Collectively, these studies demonstrated that t-DARPP drives breast cancer cell resistance to trastuzumab through inhibition of apoptotic caspase-3 and activation of pro-survival Akt signaling through its T75 residue, common among both DARPP-32 isoforms13,52,54. Here, CASP3 is linked to breast cancer.